By the Top Tier Newswire AI Desk · August 5, 2026 at 11:25 AM ET · reviewed against 5 wire stories
UROGEN PHARMA LTD (URGN) is up +14.35% in the latest session. Our newswire has captured 5 stories on URGN across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why URGN stock is up today
UroGen Pharma stock surged 14.35% to $45.65 in early August trading, driven by a strong earnings report and updated guidance. The company reported second-quarter revenue of $72.5 million, a 199.6% year-over-year increase, with ZUSDURI revenue alone reaching $50.4 million, reflecting 73% quarter-over-quarter growth. The results exceeded expectations and were accompanied by a new US patent for ZUSDURI, extending its market exclusivity through 2044.
What Happened
UroGen Pharma announced second-quarter 2026 financial results that exceeded revenue expectations and included a significant increase in ZUSDURI sales. The company reported GAAP earnings per share of -$0.28, in line with the consensus estimate. ZUSDURI, UroGen’s leading therapy for bladder cancer, generated $50.4 million in revenue, representing 73% growth from the prior quarter. This performance was supported by strong clinical durability and a newly granted US patent covering the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The patent, backed by data from the ENVISION and ATLAS trials, is set to expire in July 2044. The company also provided an updated full-year outlook and filed a Form 8-K to disclose its results of operations and financial condition.
What The Data Shows
The stock opened with a 7.8% gap up from the previous close and reached an intraday high of $45.75 before settling at $45.65. Trading volume of 0.9 million shares was 1.1 times the 3-month daily average. The stock has a market capitalization of $1.9 billion and remains unprofitable, with a trailing twelve-month EPS of -2.73 and a net margin of -94.8%. Despite the recent rally, the stock remains within its 52-week range of $15.86 to $43.93. UroGen’s revenue has increased by 52.9% over the trailing twelve months, and the stock has a beta of 1.57, indicating higher volatility than the broader market.
What To Watch
UroGen Pharma has already reported its second-quarter 2026 earnings. Investors should monitor the company’s ability to maintain its momentum in ZUSDURI sales and the impact of the new patent protection. Coverage breadth and analyst commentary will also be key indicators of market confidence.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
URGN · Aug 5 session (5-min) · +13.20% vs prior close · updated 8:57 PM ETAI sentiment, last 36h · averaged over 5 stories · 58/100 bullish
The headlines behind the move
Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline
5d agoMarketChameleonBULLISH 67Product/PR
UroGen’s ZUSDURI Revenue Surges 73% with Patent Extension Poised to Bolster Franchise Through 2044
August 5, 2026
UroGen Pharma posts a standout second quarter with ZUSDURI revenue jumping 73%, reinforced by strong clinical durability and a new US patent set to protect its leading bladder cancer therapy for nearly two decades. The company's growing portfolio and expanding clinical trials signal a durable growth trajectory despite ongoing losses.
5d agoSeeking AlphaBULLISH 56Earnings
UroGen Pharma GAAP EPS of -$0.28 in-line, revenue of $72.5M beats by $8.96M; updates FY outlook
UroGen Pharma press release (URGN): Q2 GAAP EPS of -$0.28 in-line. Revenue of $72.5M (+199.6% Y/Y) beats by $8.96M.
5d agoSEC 8-KNEUTRAL 50General
UroGen Pharma Ltd. (URGN) files 8-K
Filed: 2026-08-05 AccNo: 0001437749-26-025793 Size: 267 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
5d agoBusiness InsiderBULLISH 63Earnings
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth
6d agoSeeking AlphaBULLISH 56Earnings
UroGen Pharma Q2 2026 Earnings Preview
UroGen Pharma (URGN) is scheduled to announce Q2 earnings results on Wednesday, August 5th, before market open. The consensus EPS Estimate is -$0.27 (+74.3% Y/Y
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →